7,580.07

-140.32

-1.82%

51,770.31

-572.29

-1.09%

25,437.00

-747.70

-2.86%

2,811.84

-47.38

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,800.24

+276.31

+0.36%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

Rallybio Corporation (RLYB)

15.54 +0.01 (+0.06%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for RLYB

Chart Range Bar

Interval:

In partnership with ChartIQ

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

RallyBio tries again for reverse merger, this time with Avenzo

RallyBio tries again for reverse merger, this time with Avenzo

Candid, in a reverse merger with RallyBio, to go public

Candid, in a reverse merger with RallyBio, to go public

VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development

VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development

Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing

Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing

Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026

Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026

Rallybio to acquire Candid Therapeutics

Rallybio to acquire Candid Therapeutics

Stock Splits Matter: What’s Coming Up This Month?

Stock Splits Matter: What’s Coming Up This Month?

Mobilize your Website

View Site in Mobile | Classic

Share by: